$EAPH To Announce Updates and Progress with Manufacturing and Distribution

TORONTO, ON–(Marketwired – Dec 8, 2014) – Easton Pharmaceuticals (OTC: EAPH) announces updates to its OTC products, manufacturing and an expanded distribution agreement for North America.

Irrespective of various delays, all aspects of Easton’s business segments and initiatives have been steadily moving forward which includes soon to be disclosed and anticipated positive developments revolving around its vaporizer and medical marijuana initiatives, which is in addition to encouraging developments relating to its investment in AMFIL Technologies, a company servicing the medical marijuana and other industries who have received well positive feedback from large growers in the State of Colorado and other jurisdictions. Easton’s minority interest in its cancer drug Xilive has also had positive developments through the private efforts of its current ownership partner.

After several months of work with its suppliers, Easton’s OTC product logos are finalized, its packaging providers have been selected, payment has been forwarded and received and its OTC therapeutic products are in transit. Easton is currently in the final stage of closing and announcing new expanded North American distribution agreements which should soon result in having its OTC products stocked on shelves of various retail stores and ready for sale on high ranking websites. Additional details to soon be announced.

Due to the rapidly changing country-specific regulations in Mexico regarding the handling of Niacin, one of the ingredients in Viorra and other products, Easton has made the decision to not move forward with its manufacturing in Mexico but instead will be manufactured in Canada. Many of the delays to the launch of its OTC products were as a result of changing regulatory requirements in Mexico which was initially to be its manufacturing base. The handling and ordering of large quantities of Niacin, now considered a controlled substance in many jurisdictions in Mexico, mandates that a manufacturer may require different licenses than it currently owns, and therefore may not be permitted to handle niacin any longer, even though the quantity of Niacin per unit within its products is negligible. The products can be manufactured and sold in the United States and Canada due to Niacin being below a certain threshold set by the FDA. Once the products are manufactured they will also be transported and sold in Mexico through its distributor BMV Medica, S.A de C.V.

BMV Medica, S.A. de C.V., a Mexican regulatory company and distributor of pharmaceutical products has now included in its product list Easton Pharma’s Skin Renou HA, an anti-aging cream containing Easton’s proprietary formulation including hyaluronic acid, and Kenestrin Gel a topical, odourless and colorless treatment for arthritis. BMV Medica S.A. de C.V., is the company’s regulatory and distribution agent for Mexico, other Latin American territories and now the middle east.

About Easton Pharmaceuticals

Easton Pharmaceuticals is a specialty pharmaceutical company involved in various pharmaceutical sectors and others industries such as medical marijuana. The Company previously owned an FDA approved wound healing drug and currently owns topically-delivered drugs and therapeutic / cosmetic healthcare products focused on cancer and other health issues geared towards female sexual dysfunction, wound healing, pain, motion sickness and other conditions that are all in various stages of development. The company has ventured into the potentially lucrative medical marijuana industry through an investment into AMFIL Technologies and their groZONE anti-bacterial system and the exclusive option to purchase up to 49% in a medical marijuana grow-op business / facility which has received a letter to build from Health Canada. The company’s gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of Cannabidiol extracts.

For More Information Visit: https://www.eastonpharmaceuticalsinc.com

Safe Harbor

This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (The “Act”). In particular, when used in the preceding of discussion, the words “hope”, “positive”, “anticipate,” “pleased,” “plan,” “confident that,” “believe,” “expect,” “possible” or “intent to” and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals would be classified as speculative. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company’s products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company’s financial reports and filings.